Despite remarkable efforts of computational and predictive pharmacology to improve therapeutic strategies for complex diseases, only in a few cases have the predictions been eventually employed in the clinics. One of the reasons behind this drawback is that current predictive approaches are based only on the integration of molecular perturbation of a certain disease with drug sensitivity signatures, neglecting intrinsic properties of the drugs. Here we integrate mechanistic and chemocentric approaches to drug repositioning by developing an innovative network pharmacology strategy. We developed a multilayer network-based computational framework integrating perturbational signatures of the disease as well as intrinsic characteristics of the drugs, such as their mechanism of action and chemical structure. We present five case studies carried out on public data from The Cancer Genome Atlas, including invasive breast cancer, colon adenocarcinoma, lung squamous cell carcinoma, hepatocellular carcinoma and prostate adenocarcinoma. Our results highlight paclitaxel as a suitable drug for combination therapy for many of the considered cancer types. In addition, several non-cancer-related genes representing unusual drug targets were identified as potential candidates for pharmacological treatment of cancer.

Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study / Federico, Antonio; Fratello, Michele; Scala, Giovanni; Möbus, Lena; Pavel, Alisa; Del Giudice, Giusy; Ceccarelli, Michele; Costa, Valerio; Ciccodicola, Alfredo; Fortino, Vittorio; Serra, Angela; Greco, Dario. - In: CANCERS. - ISSN 2072-6694. - 14:8(2022), p. 2043. [10.3390/cancers14082043]

Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study

Scala, Giovanni;Ceccarelli, Michele;Costa, Valerio;Ciccodicola, Alfredo;
2022

Abstract

Despite remarkable efforts of computational and predictive pharmacology to improve therapeutic strategies for complex diseases, only in a few cases have the predictions been eventually employed in the clinics. One of the reasons behind this drawback is that current predictive approaches are based only on the integration of molecular perturbation of a certain disease with drug sensitivity signatures, neglecting intrinsic properties of the drugs. Here we integrate mechanistic and chemocentric approaches to drug repositioning by developing an innovative network pharmacology strategy. We developed a multilayer network-based computational framework integrating perturbational signatures of the disease as well as intrinsic characteristics of the drugs, such as their mechanism of action and chemical structure. We present five case studies carried out on public data from The Cancer Genome Atlas, including invasive breast cancer, colon adenocarcinoma, lung squamous cell carcinoma, hepatocellular carcinoma and prostate adenocarcinoma. Our results highlight paclitaxel as a suitable drug for combination therapy for many of the considered cancer types. In addition, several non-cancer-related genes representing unusual drug targets were identified as potential candidates for pharmacological treatment of cancer.
2022
Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study / Federico, Antonio; Fratello, Michele; Scala, Giovanni; Möbus, Lena; Pavel, Alisa; Del Giudice, Giusy; Ceccarelli, Michele; Costa, Valerio; Ciccodicola, Alfredo; Fortino, Vittorio; Serra, Angela; Greco, Dario. - In: CANCERS. - ISSN 2072-6694. - 14:8(2022), p. 2043. [10.3390/cancers14082043]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/893232
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact